This is an old revision of this page, as edited by Hernando1620 (talk | contribs) at 23:07, 4 May 2015 (Updated corporate management information as of 2015 as well as updated description of company. Please don't revert back to the 2005 information as it is no longer relevant.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 23:07, 4 May 2015 by Hernando1620 (talk | contribs) (Updated corporate management information as of 2015 as well as updated description of company. Please don't revert back to the 2005 information as it is no longer relevant.)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) | This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Neurocrine Biosciences" – news · newspapers · books · scholar · JSTOR (February 2008) (Learn how and when to remove this message) |
| Neurocrine logo | |
| Company type | Public Nasdaq: NBIX |
|---|---|
| Industry | Biotechnology |
| Founded | 1992 |
| Headquarters | San Diego, California, U.S. |
| Key people | Bill Rastetter, Chairman Kevin Gorman, CEO/President |
| Number of employees | 95 (2015) |
| Website | www.neurocrine.com |
Neurocrine Biosciences is a biopharmaceutical company founded in 1992 and located in San Diego, California. The company tooks its name from the original focus on therapies for neurological and endocrine diseases and disorders.
Neurocrine Biosciences, Inc. of San Diego discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders.
Clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine scientists are focusing on developing small molecule antagonists against G-protein coupled receptors. Our scientists possess the skills and experience necessary to bring compounds from basic research concepts to drug candidate stage.
References
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Misplaced Pages by expanding it. |